PathMaker Neurosystems

Focus: PathMaker Neurosystems is a Boston-based medical device company specializing in neurostimulation therapy for neuromotor disorders and neurology. The company is publicly traded with a focused pipeline in neuromodulation technologies.

Neurology Neuromotor disorders

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About PathMaker Neurosystems

AI assessmentNot Hiring

No open roles listed right now. Follow PathMaker Neurosystems to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

MyoRegulator®

Amyotrophic Lateral Sclerosis / Muscle Spasticity

Growth

Lead neurostimulation platform in development across two high-severity neuromotor indications with limited therapeutic options.

Pipeline & Clinical Trials

Help build intelligence for PathMaker Neurosystems

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused specialty in high-unmet-need neuromotor disorders (ALS, spasticity, spinal cord injury) with multiple clinical-stage programs — rare disease expertise commands premium in neurostimulation market
Public company status provides equity upside and institutional stability absent in pre-revenue biotech, with potential for partnerships or acquisition synergies in growing neuromodulation space
Device-plus-therapy hybrid approach (MyoRegulator®, tsDCS combinations) represents innovation frontier in neurostimulation, differentiating from traditional pharma skill sets

Watch Out For

Minimal hiring activity (2 active R&D roles) signals either efficient headcount model or limited growth trajectory — tight job market with low entry points
Early-stage clinical pipeline (Phase 1/2 only, no Phase 3 programs) means 5-7 year runway to meaningful revenue milestones, creating execution risk and potential runway pressure
No published research output (0 publications tracked) and limited public visibility into clinical progress raise questions about data generation cadence and regulatory strategy clarity

Generated by Claude from PathMaker Neurosystems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MyoRegulator®

Muscle Spasticity

N/A

Clinical Trials (1)

NCT04780191Investigation of Treatment Using the MyoRegulator® Device in Patients With Spasticity in the Lower Limb Due to Stroke

N/A

MyoRegulator® device

Muscle Spasticity

N/A

Clinical Trials (1)

NCT04742257Study Evaluating MyoRegulator® Treatment in Post-Stroke Upper Limb Spasticity

N/A